SOLICITATION NOTICE
Q -- To measure serum levels of the Prolactin (PRL) hormone using the ADVIA Centaur PRL assay using cases and controls from the Polish Breast Cancer Study.
- Notice Date
- 8/17/2007
- Notice Type
- Solicitation Notice
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- Reference-Number-NCI-70139-NV
- Response Due
- 8/31/2007
- Archive Date
- 9/15/2007
- Description
- In accordance with simplified acquisition procedures the National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Hormonal and Reproductive Epidemiology Branch (HREB) plans to procure on a sole source basis with Quest Diagnostics Nichols Institute, 14225 Newbrook Drive, Chantilly, Virginia to measure serum levels of the Prolactin (PRL) hormone using the ADVIA Centaur PRL assay using cases and controls from the Polish Breast Cancer Study. PRL is a hormone responsible for growth and development of the normal human breast and high PRL levels in serum have been associated with breast cancer risk factors including: nulliparity, oral contraceptive use, and family history of breast cancer. In addition, increased serum levels of PRL have been associated with increased breast cancer risk especially among ER+ breast cancer cases (1, 2). This procurement will build upon current research on hormones and hormone receptors in the Polish breast cancer study and allow a more complete mechanistic understanding of the relationship between serum levels of PRL ligand with breast cancer risk and tumor characteristics. Results from this work could elucidate hormone dependent mechanisms of carcinogenesis. The contractor shall measure PRL levels in 1740 serum samples (from 791 cases, 791 controls and 158 quality controls samples) provided by NCI investigators using the ADVIA Centaur Prolactin assay. The ADVIA Centaur Prolactin assay is a two-site sandwich immunoassay using direct chemiluminometric technology, which uses constant amounts of two antibodies. The first antibody, in the Lite Reagent, is a polyclonal goat anti-PRL antibody labeled with acridinium ester. The second antibody, in the Solid Phase, is a monoclonal mouse anti-PRL antibody, which is covalently coupled to paramagnetic particles. Quest Diagnostics Nichols Institute labs is uniquely qualified to perform this work in the required time and the large number of samples. Quest Diagnostics routinely performs PRL serum assays on a daily bases and is the only known contractor capable of measuring the 1740 blood sample assays. The PRL assay requires an experienced laboratory with diagnostic expertise because of the technical complexities and standards involved. The assays are available in individual laboratories but they are not set up to perform the volume of samples and time frame required. All services must be completed by April 30, 2008. In addition, Quest Diagnostics possesses unique expertise and resources for performing PRL serum assays which is critical for the success of our ongoing efforts to identify hormonally related risk factors of breast cancer and the potential association with genetic variants in the same hormone and receptor genes. This is not a solicitation for competitive quotations. However, if any interested party believes it can provide the above service, without introducing new variables into an ongoing research experiments it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. An original and one copy of the capability statements must be received in the contracting office by 1:00 p.m. EDT, on August 31, 2007. Faxed and emailed capability statements are NOT authorized. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to dm170b@nih.gov. It is the vendor's responsibility to call (301) 402-4509 to verify questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award from the NCI contractors must be registered in the Online Representations and Certifications Applications (ORCA). Please refer to http://orca.bpn.gov in order to register. In addition, contractors must be registered in the Central Contractor Registration (CCR) www.ccr.gov. No collect calls will be accepted. NAICS 621511. Size Standard $12.5M.
- Record
- SN01376213-W 20070819/070817220636 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |